Antibody-conjugated nanoparticles
OwnerFrank G. GROSVELD, Christina EICH +1inventors
InventorsFrank G. GROSVELD, Christina EICH, Luis CRUZ
Life of this patent
Estimating the term…
Abstract
The invention relates to antibody conjugates comprising an antibody and a nanoparticle conjugated to the antibody, wherein the nanoparticle comprises a payload, such as a gene editing payload. In some embodiments, the antibody-conjugated nanoparticles provide a means for treating a disease. In some embodiments, the antibody-conjugated nanoparticles are used to correct genetic defects in specific cell populations.
Claims48
An antibody conjugate comprising an antibody and a nanoparticle conjugated to the antibody, wherein the nanoparticle comprises a gene editing payload.
An antibody conjugate comprising an anti-CD34 antibody and a nanoparticle conjugated to the antibody, wherein the nanoparticle comprises a payload.
An antibody conjugate comprising an anti-gpr56 antibody and a nanoparticle conjugated to the antibody, wherein the nanoparticle comprises a payload.
An anti-CD34 antibody, comprising a heavy chain variable region (VH) comprising three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and a light chain variable region (VL) comprising three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3),
- wherein the VH comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 1;
- an HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 2;
- and an HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 3;
- and the VL comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 4;
- an LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 5;
- and an LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 6.
An anti-Gpr56 antibody, comprising a heavy chain variable region (VH) comprising three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and a light chain variable region (VL) comprising three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3),
- wherein the VH comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 7;
- an HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 8;
- and an HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 9;
- and the VL comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 10;
- an LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 11;
- and an LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 12.
A method of making an antibody conjugate, comprising:
- modifying an antibody heavy chain coding sequence to introduce a cysteine residue at or near the C-terminal end of the heavy chain constant region;
- producing a modified antibody from the modified sequence, wherein the modified antibody comprises a cysteine residue at or near the C-terminal end of the heavy chain constant region, wherein said cysteine residue has a free thiol group that is not covalently bonded to another cysteine residue;
- obtaining a nanoparticle comprising one or more polyethylene glycol (PEG) groups;
- and
- conjugating the nanoparticle to the antibody via a site-specific maleimide linkage, wherein the cysteine residue at or near the C-terminal end of the heavy chain constant region is covalently bonded to one of the one or more PEG groups of the nanoparticle.
A method of treating or ameliorating the symptoms of a genetic disorder comprising administering to a patient a composition comprising an antibody conjugate, wherein said antibody conjugate comprises an antibody and a nanoparticle conjugated to the antibody, and said nanoparticle comprises a gene editing payload.
An antibody conjugate comprising an antibody and a nanoparticle conjugated to the antibody for use in the treatment or amelioration of the symptoms of a genetic disorder, wherein the nanoparticle comprises a gene editing payload.
A method of treating or ameliorating the symptoms of a disease comprising administering to a patient a composition comprising an antibody conjugate, wherein said antibody conjugate comprises an anti-gpr56 antibody and a nanoparticle conjugated to the antibody, and said nanoparticle comprises a therapeutic payload.
An antibody conjugate comprising an anti-gpr56 antibody and a nanoparticle conjugated to the antibody for use in the treatment or amelioration of the symptoms of a disease, wherein the nanoparticle comprises a therapeutic payload.
A method of treating or ameliorating the symptoms of a disease comprising administering to a patient a composition comprising an antibody conjugate, wherein said antibody conjugate comprises an anti-CD34 antibody and a nanoparticle conjugated to the antibody, and said nanoparticle comprises a therapeutic payload.
An antibody conjugate comprising an anti-CD34 antibody and a nanoparticle conjugated to the antibody for use in the treatment or amelioration of the symptoms of a disease, wherein the nanoparticle comprises a therapeutic payload.
Dependencies are inferred from the claim text.